Highest-materiality recent filing
Esperion acquired by ARCHIMED for $3.16/share plus up to $100M in milestone payments
Cash $3.16/share + 1 CVR/share; aggregate milestone payments up to $100M based on net sales.
Esperion closes $75M acquisition of Corstasis, adds Enbumyst nasal spray
Closed acquisition of Corstasis Therapeutics for $75M cash upfront; up to $180M in milestones and royalties.
Esperion Q4 rev $168.4M (+144% Y/Y); FY25 rev $403.1M; Q4 net income $61.8M; acquires Corstasis
U.S. net product revenue Q4 $43.7M (+38% Y/Y); FY25 $159.6M (+38% Y/Y).
Esperion to acquire Corstasis for $75M upfront; adds Enbumyst nasal spray for heart failure edema
Esperion acquires Corstasis for $75M cash upfront; up to $180M in milestones plus low double-digit royalties on Enbumyst sales.
Preliminary 2025 U.S. net product sales $156-160M, up 35-38% YoY; total revenue $400-408M, up 20-23%.
Esperion Q3 total revenue up 69% to $87.3M; net loss $0.16/share
U.S. net product revenue $40.7M (+31% YoY); total collaboration revenue $46.7M (+128% YoY).
Esperion prices $75M public offering of 30M shares at $2.50 each
Offering of 30,000,000 shares at $2.50/share; net proceeds ~$70.2M (or ~$80.7M if underwriters' option exercised).
Esperion amends Q2 earnings; reports $82.4M revenue, first operating income of $7.1M
Net loss narrowed to $12.7M from $61.9M in Q2 2024; EPS loss $0.06 vs $0.33.
U.S. net product revenue $40.3M, +42% Y/Y; total prescriptions up 10% sequential.
Esperion Q1 total revenue $65.0M (-53% Y/Y); US product revenue up 41% to $34.9M
Net loss $40.5M ($0.21 EPS loss) vs net income $61.0M ($0.36 EPS) in Q1 2024 due to prior-year milestone.
Esperion CCO Eric Warren to depart effective April 18, 2025
Eric Warren stepping down as Chief Commercial Officer, effective April 18, 2025.
Esperion FY24 revenue $332.3M (+186% Y/Y); net loss narrows to $51.7M from $209.2M
FY24 total revenue $332.3M (+186% Y/Y); Q4 revenue $69.1M (+114% Y/Y).
Esperion completes $100M convertible note issuance and exchange of 2025 notes
Issued $100M aggregate principal of 5.75% Convertible Senior Subordinated Notes due June 15, 2030.
Esperion closes $150M term loan and $210M convertible debt exchange to refinance 2025 notes
Entered $150M senior secured term loan at 9.75% cash / 11.75% PIK, due Dec 2029, with minimum liquidity covenant of $50M.
Esperion Q3 revenue $51.6M (+52% YoY); net loss narrows to $29.5M
Total revenue $51.6M (+52% YoY); U.S. net product revenue $31.1M (+53% YoY).
Esperion Q2 revenue jumps 186% to $73.8M; monetizes European royalties for $304.7M
Total revenue $73.8M (+186% YoY); U.S. product revenue $28.3M (+39% YoY).
Esperion monetizes European bempedoic acid royalties for $304.7M, pays off Oberland facility
Received $304.7M from OMERS in exchange for 100% of European bempedoic acid royalty until OMERS receives 1.7x investment (≈$518M), then royalties revert to Esperion.
Esperion files Hatch-Waxman patent suit against Micro Labs over generic NEXLETOL
Filed May 8, 2024 in District of New Jersey against Micro Labs USA Inc. for NEXLETOL generic ANDA.
Esperion Q1 revenue $137.7M (+467% YoY), net income of $61.0M; FDA label expansion expands market
Total revenue $137.7M vs $24.3M YoY; U.S. net product revenue $24.8M (+46% YoY).
Eric Warren was stepping down from his position as Chief Commercial Officer of the Company, effective as of April 18, 2025.
On April 1, 2025, Antonio M. Gotto, Jr., M.D., D. Phil. notified the Board of the Company of his decision to resign from the Board, including his position as a member of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Corporate Governance Committee”), effective June 1, 2025.
On April 1, 2025, Nicole Vitullo notified the Board of Directors (the “Board”) of Esperion Therapeutics, Inc. (the “Company”) of her decision to resign from the Board, including her positions as a member of the Audit Committee of the Board (the “Audit Committee”) and Compliance Committee of the Board, effective June 1, 2025.
On April 1, 2025, upon the recommendation of the Nominating and Corporate Governance Committee, the Board elected Robert E. Hoffman to the Board, effective April 1, 2025.
JoAnne Foody will be transitioning from her role as the Company’s Chief Medical Officer and that her employment with the Company will end on or before September 16, 2024
Max materiality 1.00 · Median 0.72 · Most common event earnings